Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma

Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)

NCT02185820 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma

NCT03336073 ·Status: UNKNOWN ·Phase: PHASE2

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

NCT01497093 ·Status: COMPLETED ·Phase: PHASE1

Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma

NCT02902965 ·Status: COMPLETED ·Phase: PHASE2

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

NCT01478048 ·Status: COMPLETED ·Phase: PHASE2

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

NCT02718833 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

NCT04191616 ·Status: COMPLETED ·Phase: PHASE2

Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients

NCT02159365 ·Status: COMPLETED ·Phase: PHASE2

A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.

NCT02612779 ·Status: COMPLETED ·Phase: PHASE2

Study of Induction Treatment With Velcade and Dexamethasone for Previously Untreated Patients With Multiple Myeloma and Renal Failure

NCT01084837 ·Status: COMPLETED ·Phase: PHASE2

Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma

NCT03731832 ·Status: COMPLETED ·Phase: PHASE2

Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma

NCT01541332 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

NCT01470131 ·Status: TERMINATED ·Phase: PHASE3

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

NCT01734928 ·Status: COMPLETED ·Phase: PHASE3

An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.

NCT00555906 ·Status: COMPLETED ·Phase: PHASE2

Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma

NCT03023527 ·Status: TERMINATED ·Phase: PHASE1

Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma

NCT00813150 ·Status: COMPLETED ·Phase: PHASE3

A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma

NCT03136653 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib

NCT04243109 ·Status: TERMINATED ·Phase: PHASE2

Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma

NCT01023308 ·Status: COMPLETED ·Phase: PHASE3

Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting

NCT01946477 ·Status: COMPLETED ·Phase: PHASE2

Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma

NCT02103335 ·Status: COMPLETED ·Phase: PHASE1

Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma

NCT02548962 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex

NCT03180736 ·Status: COMPLETED ·Phase: PHASE3

A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study

NCT01311687 ·Status: COMPLETED ·Phase: PHASE3